(August 23, 2016 – Paoli, PA) Dilon Devices has been selected as one of the few recipients of a European Union Horizon 2020 research grant to spur development of its biopsy system. The 80 billion euro, seven year program is aimed at securing Europe’s global competitiveness.
Out of more than 1167 applications in the small and medium (SME) instrument category, Dilon Devices is one of only 65 companies that will receive funding through the program.
“This three million euro grant will expedite bringing our soft tissue biopsy system to the market,” says Dan Hashimshony, CEO and Founder of Dilon. “It will provide radiologists and surgeons immediate graphic characterizations of tissue abnormalities along the tip of the biopsy needle, just before samples are taken. This real-time insight can help reduce the time to a definite diagnosis and repeated biopsies. Our proprietary biopsy device can also be used in combination with other existing devices.”
The first commercial product based on Dilon’s proprietary radio frequency (RF) spectroscopy technology was the MarginProbe. It has been helping surgeons ensure clean margins in lumpectomy procedures since 2013. Based on that success, the company is expanding on its RF spectroscopy platform to develop the next generation product that will help surgeons perform biopsies.
The new product will expand Dune’s surgical oncology portfolio to include a soft tissue biopsy system with its first indication in breast tissue.
“We bring objectivity to procedures that were based mostly upon clinical judgment until now,” says Lori Chmura, President of Dilon, Inc. “Improving the standard of care around cancer surgery is what we work for every day. Our biopsy device is another step along the path to a much broader spectrum of margin detection, which we believe will lead to applications in many other types of soft tissue analysis including other types of cancer surgeries. We’re looking forward to collaborating with surgeons and radiologists in Europe and the United States during the development and testing of the system.”
About Dilon Devices
Dilon Devices was founded in 2002 by Dr. Dan Hashimshony to realize the extraordinary medical potential of its proprietary tissue characterization technology. Offering surgeons and radiologists the real-time ability to identify cancerous tissues and react immediately, this technology holds the promise for a broad range of surgical and diagnostic applications. Dilon Devices is a privately held company with offices in the U.S. and Israel. For more information, please visit www.marginprobe.com.